id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-006049-sw1hki4r	Keefe, Anthony D.	Aptamers as therapeutics	2010		.txt	text/plain	9789	510	42	Nucleic acid aptamers can be selected from pools of random-sequence oligonucleotides to bind a wide range of biomedically relevant proteins with affinities and specificities that are comparable to antibodies. Although this is true for biological nucleic acids [1] [2] [3] [4] , it was only recently that a series of technological advances allowed the development of in vitro evolutionary methods for the discovery of additional, non-biological oligonucleotides that can bind to protein targets. Since the invention of the SELEX process around 1990 (REfS 5, 6) , researchers have identified high-affinity aptamers that target a broad cross-section of protein families including cytokines, proteases, kinases, cell-surface receptors and cell-adhesion molecules (TABLE 1) . In particular, the site-specific placement of functional groups for conjugation means that the modification of aptamers after the solid-phase step (for example with high molecular mass PEG 46 ) leads to products with discrete stoichiometries and defined chemical structures. Selection of a RNA aptamer that binds to human activated protein C and inhibits its protease function	./cache/cord-006049-sw1hki4r.txt	./txt/cord-006049-sw1hki4r.txt